

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
03 February 2022 (03.02.2022)



(10) International Publication Number

WO 2022/026409 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) A61P 25/28 (2006.01)

A61P 25/16 (2006.01)

(21) International Application Number:

PCT/US2021/043216

(22) International Filing Date:

26 July 2021 (26.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/057,265 27 July 2020 (27.07.2020) US

(71) Applicant: VOYAGER THERAPEUTICS, INC.

[US/US]; 75 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: MURLIDHARAN, Giridhar; 56 Wiley Street,

Apt 2, Malden, MA 02148 (US). BROWN, Jeffrey; 3

Ridge Road, Medway, MA 02053 (US). KNOLL, Elis-

abeth; c/o Voyager Therapeutics, Inc., 75 Sidney Street,

Cambridge, MA 02139 (US). SHU, Yanqun; 43 Canal

Street, Winchester, MA (US). BALES, Kelly; c/o Voy-

ager Therapeutics, Inc., 75 Sidney Street, Cambridge, MA

02139 (US). HOU, Jinzhao; 9 Tyler Road, Lexington, MA

02420 (US). ADELUYI, Adewale; c/o Voyager Therapeu-

tics, Inc., 75 Sidney Street, Cambridge, MA 02139 (US).

HOFFMAN, Brett; c/o Voyager Therapeutics, Inc., 75 Sid-

ney Street, Cambridge, MA 02139 (US). JAGTAP, Smita;

c/o Voyager Therapeutics, Inc., 75 Sidney Street, Cam-

bridge, MA 02139 (US).

(74) Agent: LU, Yu et al.; McCarter & English, LLP, 265

Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,

TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS RELATED TO GLU-COSYLCERAMIDASE BETA DEFICIENCY

(57) Abstract: The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether *in vitro* and/or *in vivo*. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson Disease or related condition resulting from a deficiency in the quantity and/or function of GBA gene product or associated with decreased expression or protein levels of GCase protein.

WO 2022/026409 A1